MCID: PRS045
MIFTS: 44

Prostatic Hypertrophy malady

Category: Reproductive diseases

Aliases & Classifications for Prostatic Hypertrophy

About this section

Aliases & Descriptions for Prostatic Hypertrophy:

Name: Prostatic Hypertrophy 11 13 68
Benign Prostatic Hypertrophy 68
 
Prostatic Hyperplasia 68

Classifications:



External Ids:

Disease Ontology11 DOID:11132

Summaries for Prostatic Hypertrophy

About this section
MalaCards based summary: Prostatic Hypertrophy, also known as benign prostatic hypertrophy, is related to hypogonadism and prostatitis, and has symptoms including prostatism and prostatism. An important gene associated with Prostatic Hypertrophy is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways are Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics and Ovarian Infertility Genes. The drugs prazosin and finasteride have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and spinal cord, and related mouse phenotypes are digestive/alimentary and cardiovascular system.

Related Diseases for Prostatic Hypertrophy

About this section

Diseases related to Prostatic Hypertrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 132)
idRelated DiseaseScoreTop Affiliating Genes
1hypogonadism29.9AR, CYP19A1, KLK3
2prostatitis10.9
3gastric cardia adenocarcinoma10.6ESR1, KLK3
4right bundle branch block10.6AR, KLK3
5colon mucinous adenocarcinoma10.6AR, KLK3
6riedel's fibrosing thyroiditis10.6CYP19A1, ESR1
7vhl-related pheochromocytoma10.6AR, ESR1
8dystonia-parkinsonism, x-linked10.5AR, CYP19A1
9vulvar angiokeratoma10.5ESR1, PGR
10central nervous system organ benign neoplasm10.5ESR1, PGR
11fallopian tube benign neoplasm10.5ESR1, PGR
12appendix leiomyoma10.5ESR1, PGR
13mixed cell adenoma10.5ESR1, PGR
14gelatinous ascites10.5ESR1, PGR
15autoimmune disease of central nervous system10.5AR, KLK3
16gastrojejunal ulcer10.5AR, CYP19A1
17deafness, autosomal dominant 8/1210.5ESR1, PGR
18perinatal intestinal perforation10.5ESR1, PGR
19trigeminal nerve disease10.5ESR1, PGR
20glottis verrucous carcinoma10.5ESR1, PGR
21epilepsy, idiopathic generalized 1110.5AR, CYP19A1
22asthma susceptibility 510.5ESR1, PGR
23amyloid tumor10.5ESR1, PGR
24extracranial neuroblastoma10.5ESR1, PGR
25malignant mediastinal neurogenic neoplasm10.5ESR1, PGR
26mollaret meningitis10.5CYP19A1, PGR
27uterine body mixed cancer10.5ESR1, PGR
28parkinson disease, juvenile, type 210.5CYP19A1, ESR1
29malignant secondary hypertension10.5CYP19A1, PGR
30infiltrative basal cell carcinoma10.5ESR1, PGR
31fallopian tube germ cell cancer10.5ESR1, PGR
32ocular cancer10.5AR, ESR1
33bartholin's gland small cell carcinoma10.5AR, KLK3
34aromatase excess syndrome10.5CYP19A1, ESR1
35bile duct mucoepidermoid carcinoma10.5ESR1, PGR
36cholesteatoma of external ear10.5ESR1, PGR
37pilar sheath acanthoma10.5ESR1, PGR
38bladder clear cell adenocarcinoma10.4ESR1, PGR
39anomalous left coronary artery from the pulmonary artery10.4ESR1, PGR
40adenosine monophosphate deaminase 1 deficiency10.4ESR1, PGR
41cell type benign neoplasm10.4ESR1, PGR
42cartilage cancer10.4ESR1, PGR
43vibratory urticaria10.4ESR1, PGR
44thoracic benign neoplasm10.4ESR1, PGR
45clear cell hidradenoma10.4AR, PGR
46gastrointestinal system benign neoplasm10.4ESR1, PGR
47leiomyosarcoma10.4ESR1, PGR
48poliomyelitis10.4AR, PGR
49pleomorphic carcinoma10.4ESR1, PGR
50glioblastoma classical subtype10.3AR, CYP19A1, KLK3

Comorbidity relations with Prostatic Hypertrophy via Phenotypic Disease Network (PDN):

(show top 50)    (show all 51)
Acute CystitisAcute Kidney Failure
AnthracosisAsbestosis
Bladder DiseaseBladder Neck Obstruction
Chronic Kidney FailureCoronary Artery Disease
Cystitis CysticaCystitis
First-Degree Atrioventricular BlockGeneralized Atherosclerosis
GoutHydronephrosis
Interstitial CystitisIschemic Heart Disease
Left Bundle Branch HemiblockLipoma of Spermatic Cord
Low Compliance BladderNephrolithiasis
Neurogenic BladderParkinson Disease, Late-Onset
Pelvic VaricesPinta Disease
PneumoconiosisPostinflammatory Pulmonary Fibrosis
Primary HyperoxaluriaProstate Cancer
Prostate Carcinoma in SituBalanoposthitis
Epididymo-OrchitisInfected Hydrocele
Penile DiseasePeyronie's Disease
Prostate CalculusProstate Disease
ProstatitisProstatocystitis
SpermatoceleRenal Pelvis Carcinoma
Right Bundle Branch BlockSilicosis
Ureter CancerUreterolithiasis
Urethral CalculusUrethral Cancer
Urethral StrictureUrethritis
Urinary Tract ObstructionVaricocele

Graphical network of the top 20 diseases related to Prostatic Hypertrophy:



Diseases related to prostatic hypertrophy

Symptoms & Phenotypes for Prostatic Hypertrophy

About this section

UMLS symptoms related to Prostatic Hypertrophy:


prostatism

MGI Mouse Phenotypes related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053818.6AR, CD36, CYP19A1, EGF, ESR1, FGF8
2MP:00053858.5ADRA1A, AR, CD36, CYP19A1, ESR1, FGF8
3MP:00053698.4ADRA1A, AR, CD36, CYP19A1, ESR1, FGF8
4MP:00053868.2ADRA1A, AR, CD36, CYP19A1, ESR1, FGF8
5MP:00053798.2AR, CD36, CYP19A1, EGF, ESR1, FGF8
6MP:00053678.1ADRA1A, AR, CD36, CYP19A1, ESR1, FGF8

Drugs & Therapeutics for Prostatic Hypertrophy

About this section

Drugs for Prostatic Hypertrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 106)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Tamsulosinapproved, investigationalPhase 4, Phase 3, Phase 1157106133-20-4129211
Synonyms:
(R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
106133-20-4
5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide
5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzenesulfonamide
5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide
5-[2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide
5-{(2R)-2-[(2-{[2-(ethyloxy)phenyl]oxy}ethyl)amino]propyl}-2-(methyloxy)benzenesulfonamide
AC1L2V76
BIDD:GT0261
C07124
C20H28N2O5S
CHEBI:9398
CHEMBL836
CID129211
D08560
DB00706
FT-0082894
Flomax
Flomax (TN)
 
Flowmax
HMS2090P15
Harnal
LS-31578
MolPort-003-850-388
NCGC00167442-01
STK626950
TAMSULOSIN
Tamsolusin
Tamsulon
Tamsulon (TN)
Tamsulosin
Tamsulosin (INN)
Tamsulosin [INN:BAN]
Tamsulosina
Tamsulosina [INN-Spanish]
Tamsulosine
Tamsulosine [INN-French]
Tamsulosinum
Tamsulosinum [INN-Latin]
UNII-G3P28OML5I
YM-617
2
Alfuzosinapproved, investigationalPhase 4, Phase 3, Phase 25181403-80-72092
Synonyms:
(±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide
128707-53-9
81403-68-1 (hydrochloride)
81403-80-7
86163-78-2
AB00514667
AC1L1CWF
Alfusosine
Alfuzosin
Alfuzosin (INN)
Alfuzosin [INN:BAN]
Alfuzosina
Alfuzosina [Spanish]
Alfuzosine
Alfuzosine [French]
Alfuzosinum
Alfuzosinum [Latin]
BPBio1_000357
BRD-A09056319-001-02-2
BRD-A09056319-003-03-6
BSPBio_000323
BSPBio_002646
Bio-0003
C19H27N5O4
CHEBI:51141
CHEMBL709
CID2092
CPD000466340
D07124
DB00346
HMS1922P11
HMS2051I10
HMS2093O06
HSDB 7290
 
KBio3_001866
KBioGR_001616
L001317
LS-70106
MLS000759449
MLS001424027
MolPort-003-666-623
N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide
N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide
N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide
NCGC00095152-01
NCGC00095152-02
NCGC00095152-03
NCGC00095152-04
NCGC00095152-05
Prestwick0_000322
Prestwick1_000322
Prestwick2_000322
Prestwick3_000322
SAM001246638
SL 77-499
SL 77499
SMR000466340
SPBio_000429
SPBio_002244
SPECTRUM1505263
STK643675
Spectrum2_000505
Spectrum3_001063
Spectrum4_001208
Spectrum5_000817
UNII-90347YTW5F
Xatral (TN)
alfuzosin
alphuzosine
3
Testosteroneapproved, investigationalPhase 4, Phase 3, Phase 254658-22-06013
Synonyms:
(+)-testosterone
(+-)-8-iso-testosterone
(+-)-retrotestosterone
(+-)-testosterone
(17b)-17-hydroxy-androst-4-en-3-one
(17beta)-17-Hydroxyandrost-4-en-3-one
(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
13-Iso-testosterone
17-Hydroxy-(17-beta)-androst-4-en-3-one
17-Hydroxy-(17beta)-androst-4-en-3-one
17-Hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one
17-Hydroxy-D4-androsten-3-one
17-Hydroxy-androst-4-en-3-one
17-beta-Hydroxy-delta(sup 4)-androsten-3-one
17-beta-Hydroxyandrost-4-en-3-one
17?-Hydroxy-4-androsten-3-one
17a-Hydroxy-(13a)-androst-4-en-3-one
17a-Hydroxy-13a-androst-4-en-3-one
17a-Hydroxy-14b-androst-4-en-3-one
17a-Hydroxy-androst-4-en-3-one
17b-Hydroxy-(10a)-androst-4-en-3-one
17b-Hydroxy-(13a)-androst-4-en-3-one
17b-Hydroxy-(8a)-androst-4-en-3-one
17b-Hydroxy-(8a,10a)-androst-4-en-3-one
17b-Hydroxy-(9b)-androst-4-en-3-one
17b-Hydroxy-(9b,10a)-androst-4-en-3-one
17b-Hydroxy-13a-androst-4-en-3-one
17b-Hydroxy-8a-androst-4-en-3-one
17b-Hydroxy-D4-androsten-3-one
17b-Hydroxy-androst-4-en-3-on
17b-Hydroxy-androst-4-en-3-one
17b-Hydroxyandrost-4-en-3-one
17b-Hydroxyandrost-4-ene-3-one
17b-Testosterone
17b-hydroxy-4-androsten-3-one
17beta-Hydroxy-3-oxo-4-androstene
17beta-Hydroxy-4-androsten-3-one
17beta-Hydroxy-delta(sup4)-androsten-3-one
17beta-Hydroxyandrost-4-en-3-one
17beta-Hydroxyandrost-4-ene-3-one
17beta-hydroxy-4-androsten-3-one
4-Androsten-17?-ol-3-one
4-Androsten-17beta-ol-3-one
4-Androsten-3-one-17b-ol
4-androsten-17β-ol-3-one
4-androstene-17beta-ol-3-one
46923_FLUKA
46923_RIEDEL
58-22-0
7-beta-Hydroxyandrost-4-en-3-one
8-Iso-testosterone
9b,10a-Testosterone
9b-Testosterone
AA 2500
AC-14899
AC1L1LM0
Andriol
Andro
Andro 100
Andro L.A. 200
AndroGel
Androderm
Androderm (TN)
Androgel
Androgel (TN)
Android 10
Android 25
Android 5
Androlin
Andronaq
Andronate 100
Andronate 200
Andropatch
Andropository 200
Androsorb
Androst-4-en-17b-ol-3-one
Androst-4-en-17beta-ol-3-one
Androst-4-ene-17b-ol-3-one
Andrusol
Andryl 200
B5DEE83F-632B-48A1-A0ED-A51E7F13DF2E
BIDD:ER0555
BIM-0061761.0001
Beta Testosterone
Bio-0678
Bio-T-Gel
C00535
CCRIS 574
CDB 111C
CHEBI:17347
CHEMBL386630
CID6013
CMC_13449
COL 1621
CP 601B
CPD000058344
Cristerona T
Cristerone T
D00075
D4-Androsten-17b-ol-3-one
DB00624
Dea No. 4000
Delatest
Delatestryl
Depo-Testadiol
Depo-Testosterone
Depo-Testosterone Cypionate
Depotest
EINECS 200-370-5
Epitestosteron
Everone 200
Geno-Cristaux Gremy
Geno-cristaux Gremy
Geno-cristaux gremy
HMS2052N11
HSDB 3398
Halotensin
Homosteron
Homosterone
 
Intrinsa
LMST02020002
LS-148813
LibiGel
Libigel
Lumitestosteron
MLS000563091
MLS001032098
MLS001306401
MLS002174283
Malerone
Malestrone
Malestrone (amps)
Malogen in Oil
Malogen, Aquaspension Injection
Malogen, aquaspension injection
Mertestate
Metandren
Methyltestosterone
MolPort-002-506-901
NCGC00091018-01
NSC 9700
Neo-Hombreol F
Neo-Testis
Neo-testis
Neotestis
Oreton
Oreton F
Oreton Methyl
Oreton-F
Orquisteron
Perandren
Percutacrine Androgenique
Percutacrine androgenique
Primotest
Primoteston
Rac-17b-hydroxy-(13a)androst-4-en-3-one
Rac-17b-hydroxy-(8a)-androst-4-en-3-one
Rac-17b-hydroxy-(9b,10a)androst-4-en-3-one
Rac-17b-hydroxy-androst-4-en-3-one
Relibra
Retrotestosterone
S00309
S2033_Selleck
SAM001246921
SMR000058344
SMR001261453
Scheinpharm Testone-Cyp
Striant
Striant (TN)
Sustanon
Sustanone
Sustason 250
Synandrol F
T-Cypionate
T1500_SIGMA
T5411_FLUKA
T5411_SIGMA
TES
Teslen
Testamone 100
Testandrone
Testaqua
Testiculosterone
Testim
Testim (TN)
Testobase
Testoderm
Testoderm Tts
Testogel
Testoject-50
Testolent
Testolin
Testopel Pellets
Testopropon
Testosteroid
Testosteron
Testosterona
Testosterona [INN-Spanish]
Testosterone
Testosterone (JAN/USP)
Testosterone Cypionate
Testosterone Enanthate
Testosterone Hydrate
Testosterone [Androgenic steroids, anabolic]
Testosterone [INN:BAN]
Testosterone and its esters
Testosterone hydrate
Testosterone solution
Testosteronum
Testosteronum [INN-Latin]
Testostosterone
Testostérone
Testoviron
Testoviron Schering
Testoviron T
Testoxyl
Testred
Testred Cypionate 200
Testrin-P.A
Testro AQ
Testro Aq
Testrone
Testryl
Tostrelle
Tostrex
Trans-Testosterone
UNII-3XMK78S47O
Viatrel
Virilon
Virilon IM
Virormone
Virosterone
ZINC06500184
beta testosterone
delta(sup 4)-Androsten-17(beta)-ol-3-one
delta4-Androsten-17beta-ol-3-one
delta4-androsten-17b-ol-3-one
testosterone
trans-Testosterone
4
RocuroniumapprovedPhase 4261119302-91-9, 143558-00-3441290
Synonyms:
(2beta,3alpha,5alpha,16beta,17beta)-17-acetoxy-16-(1-allylpyrrolidinium-1-yl)-3-hydroxy-2-(morpholin-4-yl)androstane
143558-00-3
AC1L9AWM
BIDD:GT0360
C07556
CHEBI:8884
CID441290
 
DB00728
Esmeron
HMS2090E03
NCGC00167433-01
Rocuronium
Rocuronium bromide
Zemuron
[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
5
DihydrotachysterolapprovedPhase 41667-96-95281010, 5311071
Synonyms:
(1S,3E,4S)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol
(1S,3E,4S)-3-[(2E)-2-[(3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol
(3E)-3-[(2E)-2-[1-[(E)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol
(3S,5E,7E,10S,22E)-9,10-secoergosta-5,7,22-trien-3-ol
(3Z)-3-[(2E)-2-[1-[(E)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol
67-96-9
9,10-Secoergosta-5,7,22-trien-3beta-ol
A.T. 10
AC1NQXW4
AC1NS4C8
AC1NSJXZ
AC1NWALO
AT 10
Anti-tetany substance 10
Antitanil
C06957
C28H46O
CHEBI:4591
CID5281010
CID5311071
CID5353584
CID5702045
Calcamine
D9257_FLUKA
D9257_SIGMA
DB01070
DHT2
Dht Intensol
 
Dht(sub 2)
Dichystrolum
Dihidrotaquisterol
Dihidrotaquisterol [INN-Spanish]
Dihydral
Dihydrotachysterol
Dihydrotachysterol [INN:BAN:JAN]
Dihydrotachysterol(sub 2)
Dihydrotachysterolum
Dihydrotachysterolum [INN-Latin]
Diidrotachisterolo
Diidrotachisterolo [DCIT]
Dygratyl
EINECS 200-672-7
HMS502L11
HSDB 3314
Hytakerol
IDI1_000869
LMST03010056
LS-148512
MolPort-003-941-198
NCGC00166147-01
NCGC00166147-02
Parterol
ST075187
Tachyrol
Tachystin
Vitamin D4
dihydrotachysterol
6
MethyltestosteroneapprovedPhase 4, Phase 3, Phase 254658-18-46010
Synonyms:
17(alpha)-Methyl-delta(4)-androsten-17(beta)-ol-3-one
17-Methyltestosterone
17-beta-Hydroxy-17-methylandrost-4-en-3-one
17-methyltestosterone
17alpha-Methyl-3-oxo-4-androsten-17beta-ol
17alpha-Methyl-delta(4)-androsten-17beta-ol-3-one
17alpha-Methyltestosterone
17alpha-methyl-delta-androsten-17beta-ol-3-one
17alpha-methyltestosterone
 
17beta-Hydroxy-17-methylandrost-4-en-3-one
17α-methyl-Δ4-androsten-17β-ol-3-one
17α-methyltestosterone
4-Androstene-17alpha-methyl-17beta-ol-3-one
Android
Methyltestosterone
Methyltestosteronum
Metiltestosterona
NSC-9701
Testred
Virilon
7
Dutasterideapproved, investigationalPhase 4, Phase 3, Phase 2114164656-23-9152945, 6918296
Synonyms:
(1S,3aS,3bS,5aR,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
(1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
(5.alpha.,17.beta.)-N-{2,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide
(5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
164656-23-9
AC1L49EM
AC1OCF98
Avodart
Avodart (TN)
Avodart, Dutasteride
Avolve
Bio-0167
C27H30F6N2O2
CHEBI:132773
CHEMBL1200969
CHEMBL283245
CID152945
CID6918296
CID9914880
D03820
 
DB01126
Duagen
Dutasteride
Dutasteride (JAN/USAN/INN)
Dutasteride [USAN]
FT-0080365
GG 745
GG-745
GI 198745
GI-198745
GI-198745X
LS-173584
MolPort-003-666-660
MolPort-003-847-041
N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
NSC740477
S1202_Selleck
UNII-O0J6XJN02I
ZINC03932831
alpha,alpha,alpha,Alpha',alpha',alpha'-hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide
alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide
8
MivacuriumapprovedPhase 410106791-40-6, 133814-19-45281042
Synonyms:
(R)-1,2,3,4-Tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium chloride, (E)-4-octenedioate (2:1)
106791-40-6
106861-44-3
133814-19-4
AC1NQXXZ
AC1NQXZZ
BW B109OU dichloride
BW-B1090U
BW-B109OU
BWB109OU
C07550
C58H80N2O14
CHEMBL984
CID5281042
CID5281080
Chlorure de mivacurium
 
Chlorure de mivacurium [French]
Cloruro de mivacurio
Cloruro de mivacurio [Spanish]
D00763
DB01226
LS-172022
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER
MIVACURIUM CHLORIDE
Mivacron
Mivacron (TN)
Mivacurii chloridum
Mivacurii chloridum [Latin]
Mivacurium
Mivacurium chloride (USAN/INN)
Mivacurium chloride [USAN:INN:BAN]
NCGC00167469-01
bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate
bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate dichloride
9
DoxazosinapprovedPhase 4, Phase 35774191-85-83157
Synonyms:
1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin
1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[4-(1,4-benzodioxan-2-yl)carpiperazin-1-yl)]-6,7-dimethoxyquinazoline mesylate
2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-bis(methyloxy)quinazolin-4-amine
2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
2-{4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine
74191-85-8
77883-43-3 (mesylate)
AC-11062
AC1L1FAT
AC1Q470P
AC1Q4EXN
AKOS001681453
BPBio1_000963
BRD-A13188892-066-03-3
BSPBio_000875
C06970
C23H25N5O5
CHEBI:4708
CHEMBL707
CID3157
CPD000097306
Cardura XL (TN)
Cardura-1
Cardura-2
Cardura-4
ChemDiv2_005017
D07874
D9815_SIGMA
DB00590
 
Doxazosin (INN)
Doxazosin [INN:BAN]
Doxazosin mesilate
Doxazosina
Doxazosina [Spanish]
Doxazosine
Doxazosine [French]
Doxazosinum
Doxazosinum [Latin]
HMS1383E01
HMS2090C20
I06-1346
IDI1_003732
L000738
LS-110228
Lopac0_000474
MolPort-001-684-491
NCGC00018158-06
NCGC00089775-02
Normothen
Oprea1_259518
Prestwick0_000858
Prestwick1_000858
Prestwick2_000858
Prestwick3_000858
SAM002589981
SPBio_002796
UK 33274
UK-33274
UNII-NW1291F1W8
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone
doxazosin
10
SilodosinapprovedPhase 422160970-54-7
Synonyms:
KAD 3213
 
KMD 3213
Rapaflo
Urief
11
MirabegronapprovedPhase 489223673-61-8
Synonyms:
 
Myrbetriq
12
DihydrotestosteroneillicitPhase 415521-18-610635
Synonyms:
17-Hydroxy-androstan-3-one
17-Hydroxyandrostan-3-one
17b-Hydroxy-3-androstanone
17beta-Hydroxy-5alpha-androstan-3-one
17beta-Hydroxy-5alpha-androstane-3-one
17beta-Hydroxyandrostan-3-one
17beta-hydroxy-5alpha-androstan-3-one
17β-hydroxy-3-oxo-5α-androstanone
17β-hydroxy-5α-androstan-3-one
4,5a-Dihydrotestosterone
4-Dihydrotestosterone
5-a-Androstanolone
5-alpha-Androstanolone
5A-Androstan-3-on-17B-ol
5B-Androstan-3-on-17B-ol
5a-Androstan-17b-ol-3-one
5a-Dihydrotestosterone
5alpha-Dihydrotestosterone
 
5alpha-androstan-17beta-ol-3-one
5α-DHT
Anaboleen
Anabolex
Andractim
Androlone
Androstalone
Androstanolone
Cristerona MB
DHT
Dihydrotestosteron
Dihydrotestosterone
Dihydrotestostérone
Drolban
Neodrol
Proteina
Protona
Stanaprol
Stanolone
Stanorone
13Cholinergic AgentsPhase 4, Phase 3, Phase 23846
14Adrenergic AntagonistsPhase 4, Phase 3, Phase 21535
15Neuromuscular AgentsPhase 4, Phase 3, Phase 21129
16Neurotransmitter AgentsPhase 4, Phase 3, Phase 217734
17Adrenergic AgentsPhase 4, Phase 3, Phase 25140
18Adrenergic alpha-1 Receptor AntagonistsPhase 4, Phase 3, Phase 2470
19Adrenergic alpha-AntagonistsPhase 4, Phase 3, Phase 2727
20Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 222776
21Steroid Synthesis InhibitorsPhase 4, Phase 3, Phase 1, Phase 21718
22Adrenergic AgonistsPhase 42877
23Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 1, Phase 212767
24Antihypertensive AgentsPhase 4, Phase 34095
25Testosterone undecanoatePhase 4, Phase 3, Phase 2546
26
Testosterone enanthatePhase 4, Phase 3, Phase 2546315-37-79416
Synonyms:
17-((1-Oxoheptyl)oxy)androst-4-en-3-one
17-Hydroxyandrost-4-en-3-one, 17-heptanoate
17-Hydroxyandrost-4-en-3-one, 17-heptanoic acid
17beta-Enanthoxyandrost-4-en-3-one
17beta-Hydroxyandrost-4-en-3-one enanthate
4-Androsten-17beta-ol-3-one 17-enanthate
4-Androsten-3-one 17beta-enanthate
Androgyn L.A.
Andropository
Androtardyl
Atlatest
DEA No. 4000
DePatestrye
Delatest
Delatestryl
Depo-Testro Med
Ditate
Durathate
Everone
 
Exten test
Malogen L.A.
Malogen L.A.200
Orquisteron-E
Primotestone
Reposo TMD
Testanthate
Testate
Testenate
Testinon
Testoenant
Testonenant
Testosterone 17-enanthate
Testosterone 17beta-heptanoate
Testosterone 17beta-heptanoic acid
Testosterone enantate
Testosterone heptoate
Testosterone heptoic acid
Testosterone heptylate
Testosterone oenanthate
Testostroval
27Testosterone 17 beta-cypionatePhase 4, Phase 3, Phase 2546
28Antineoplastic Agents, HormonalPhase 4, Phase 25407
29HormonesPhase 4, Phase 3, Phase 1, Phase 213979
30Neuromuscular Nondepolarizing AgentsPhase 4248
31Cholinergic AntagonistsPhase 41658
32
AtracuriumPhase 48064228-79-147319
Synonyms:
2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium]
5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate
64228-79-1
64228-81-5 (besylate)
AB00514743
AC1L2HUF
AC1Q67HR
Atracurium
Atracurium Dibesylate
BPBio1_000011
BRN 1523633
BSPBio_000009
 
C07548
C53H70N2O12
CHEBI:2914
CHEMBL1360
CID47319
DB00732
HMS2090I21
LS-86151
MolPort-005-932-641
Prestwick1_000005
Prestwick2_000005
Prestwick3_000005
SPBio_001930
UNII-2GQ1IRY63P
33AnestheticsPhase 49001
34Muscarinic AntagonistsPhase 41134
35Neuromuscular Blocking AgentsPhase 4414
36Hormone AntagonistsPhase 4, Phase 3, Phase 1, Phase 212778
37AndrogensPhase 4, Phase 3, Phase 21275
38Anabolic AgentsPhase 4, Phase 2499
395-alpha Reductase InhibitorsPhase 4, Phase 3, Phase 1, Phase 2168
40Solifenacin succinatePhase 4112242478-38-2
41Adrenergic beta-AgonistsPhase 41640
42Adrenergic beta-3 Receptor AgonistsPhase 497
43
AcetylcholineapprovedPhase 3, Phase 277651-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
O-Acetylcholine
acetylcholine chloride
44
FinasterideapprovedPhase 3, Phase 1, Phase 26898319-26-757363
Synonyms:
(1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(1,1-dimethylethyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(tert-butyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
(5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
17beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androst-1-en-3-one
34202_FLUKA
34202_RIEDEL
98319-26-7
AB00513901
AC1L1MUF
AC1Q5L2C
Andozac
BPBio1_001027
BRD-K01095011-001-03-5
BRN 4269024
BSPBio_000933
C23H36N2O2
CCRIS 7438
CHEBI:5062
CHEMBL710
CID57363
CPD000466304
Cahill May Roberts Brand of Finasteride
Chibro Proscar
Chibro-Proscar
Chibro-proscar
D00321
D018120
DB01216
DB07774
Eucoprost
F1293_SIGMA
FIT
FT-0082891
Finasterida
Finasterida [INN-Spanish]
Finasteride (USP/INN)
Finasteride [USAN:INN:BAN]
Finasteridum
Finasteridum [INN-Latin]
Finastid
Finpecia
Frosst Iberica Brand of Finasteride
HMS1570O15
HMS2051F09
 
HMS2090G22
HSDB 6793
KS-1058
L-652,931
LS-7397
Lipha Brand of Finasteride
MK 0906
MK 906
MK-0906
MK-906
MK906
MLS000759404
MLS001165768
MLS001424046
MSD Brand of Finasteride
MSD Chibropharm Brand of Finasteride
Merck Brand 1 of Finasteride
Merck Brand 2 of Finasteride
Merck Frosst Brand 1 of Finasteride
Merck Frosst Brand 2 of Finasteride
Merck Sharp & Dhome Brand 2 of Finasteride
Merck Sharp & Dohme Brand 1 of Finasteride
MolPort-002-500-272
N-(2-Methyl-2-propyl)-3-oxo-4-aza-5-alpha-androst-1-ene-17-beta-carboxamide
N-(2-methyl-2-propyl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-carboxamide
N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
Prestwick0_000717
Prestwick1_000717
Prestwick2_000717
Prestwick3_000717
Propecia
Propecia (TN)
Propeshia
Proscar
Proscar (TN)
Proscar, Propecia, Finasteride
Prostide
S1197_Selleck
SAM001246541
SMR000466304
SPBio_002854
UNII-57GNO57U7G
YM-152
ZINC03782599
finasteride
45
MetforminapprovedPhase 31746657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
46
Magnesium oxideapprovedPhase 3631309-48-414792
Synonyms:
 
Magmitt
47
Cetrorelixapproved, investigationalPhase 363120287-85-616129715, 25074887
Synonyms:
120287-85-6
Ac-D-Nal(2)-D-Phe(pCl)-D-Pal(3)-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2
CHEBI:59224
CHEMBL1200490
Cetrorelix
Cetrorelix (INN)
Cetrorelixum
 
Cetrorelixum [INN-Latin]
Cetrotide (TN)
D07665
HS-2008
N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N5-carbomoyl-D-ornithyl-L-leucyl-L-prolyl-D-alaninamide
N-acetyl-3-(naphthalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-L-tyrosyl-N(5)-carbamoyl-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide
SB 75
SB-75
48
Tadalafilapproved, investigationalPhase 3, Phase 2, Phase 1149171596-29-5110635
Synonyms:
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
171596-29-5
1xoz
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
AC1L380B
ADCIRCA
Acdirca
Adcirca
C429886
CHEBI:41488
CHEMBL779
CID110635
CPD000466321
Cialis
Cialis (TN)
Cialis, GF 196960, IC 351, ICOS 351, Tadalafil
D02008
DB00820
FT-0080116
GF 196960
GF-196960
 
HMS2051N17
HSDB 7303
IC 351
IC-351
ICOS 351
Ic351
KS-1117
LS-186558
LS-187015
LS-187770
Lilly brand of tadalafil
MLS000759426
MLS001165782
MLS001195644
MLS001424132
MolPort-002-885-864
S1512_Selleck
SAM001246586
SMR000466321
Tadalafil
Tadalafil (JAN/USAN/INN)
Tadalafil [USAN]
Tadanafil
UNII-742SXX0ICT
ZINC03993855
49
Inulinapproved, nutraceuticalPhase 31029005-80-524763
Synonyms:
(2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethy
189444-25-5
887747-94-6
AC1L2NNM
AI3-19506
CID24763
DB00638
 
EINECS 232-684-3
INULIN
Inulin USP 27
Inulin [BAN]
Inulin and sodium chloride
Inulin from Jerusalem artichokes
LS-186416
LS-187349
50Botulinum Toxins, Type APhase 3, Phase 2630

Interventional clinical trials:

(show top 50)    (show all 89)
idNameStatusNCT IDPhase
1Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate HypertrophyCompletedNCT00542165Phase 4
2Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPHCompletedNCT01260129Phase 4
3Effect of Deep BLock on Intraoperative Surgical ConditionsCompletedNCT01631149Phase 4
4Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic HyperplasiaCompletedNCT00771394Phase 4
5Efficacy Study for Use of Dutasteride (Avodart) With Testosterone ReplacementCompletedNCT00752869Phase 4
6Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate CancerCompletedNCT00375765Phase 4
7Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic ObstructionCompletedNCT00827814Phase 4
8Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate EnlargementCompletedNCT01294592Phase 4
9Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate EnlargementCompletedNCT00648323Phase 4
10TRADE-Testosterone Replacement and Dutasteride EffectivenessCompletedNCT00194675Phase 4
11Efficacy of Prunus Domestica Extract in BPHCompletedNCT02702947Phase 4
12Alpha-Blockers in Allergic Rhinitis (MAN 01)CompletedNCT01946035Phase 4
13A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)RecruitingNCT02656173Phase 4
14Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 YearsRecruitingNCT02757963Phase 4
15Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia RepairNot yet recruitingNCT02958878Phase 4
16A-botulinic Toxin for Symptomatic Benign Prostate HypertrophyUnknown statusNCT01275521Phase 3
17Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)CompletedNCT00663858Phase 3
18The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the ProstateCompletedNCT00427219Phase 2, Phase 3
19Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)CompletedNCT00670306Phase 3
20Medical Therapy of Prostatic Symptoms (MTOPS)CompletedNCT00021814Phase 3
21Clinical Trial in Males With BPH (Enlarged Prostate)CompletedNCT00029822Phase 3
22"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased RiskCompletedNCT00056407Phase 3
23A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary SymptomsCompletedNCT01139762Phase 3
24Intraprostatic Botulinum Toxin Type "A" Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical TherapyCompletedNCT01566292Phase 2, Phase 3
25Combination of Metformine/Inulin Versus Metformin on Prostate Benign Hyperplasia in Metabolic SyndromeCompletedNCT02778776Phase 3
26Study to Assess the Efficacy of Medi-Tate TIND DeviceActive, not recruitingNCT02145208Phase 3
27Cetrorelix Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)TerminatedNCT00449150Phase 3
28JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)TerminatedNCT01830829Phase 3
29Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS)TerminatedNCT00688948Phase 2, Phase 3
30H-36731: Finasteride in Management of Elevated Red Blood CellsWithdrawnNCT02548117Phase 3
31A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).Unknown statusNCT00044226Phase 2
32Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate HypertrophyCompletedNCT00461123Phase 2
33Clinical Results of Odyliresin (Iresine Celosia) in Symptomatic Benign Prostatic HyperplasiaCompletedNCT02977832Phase 2
34Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic HyperplasiaCompletedNCT00386009Phase 2
35Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate)CompletedNCT00037141Phase 1, Phase 2
36A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After SupplementationCompletedNCT00154843Phase 2
37Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous ChorioretinopathyCompletedNCT01227993Phase 1, Phase 2
385-Alpha Reductase and Anabolic Effects of TestosteroneCompletedNCT00475501Phase 2
39Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral TestosteroneCompletedNCT00161421Phase 2
40Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH)RecruitingNCT02676544Phase 1, Phase 2
41Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate HypertrophyRecruitingNCT02961114Phase 1, Phase 2
42Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 GramsRecruitingNCT02396420Phase 2
43Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate BrachytherapyRecruitingNCT01446991Phase 2
44Testosterone Plus Finasteride Treatment After Spinal Cord InjuryRecruitingNCT02248701Phase 2
45A Study in Men With Benign Prostatic HyperplasiaTerminatedNCT01097707Phase 2
46A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)TerminatedNCT00651807Phase 2
47Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)CompletedNCT01330927Phase 1
48Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic HyperplasiaRecruitingNCT02592473Phase 1
49A Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 in Healthy Male SubjectsNot yet recruitingNCT02615782Phase 1
50Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)Unknown statusNCT00256399

Search NIH Clinical Center for Prostatic Hypertrophy

Inferred drug relations via UMLS68/NDF-RT46:

Genetic Tests for Prostatic Hypertrophy

About this section

Anatomical Context for Prostatic Hypertrophy

About this section

MalaCards organs/tissues related to Prostatic Hypertrophy:

36
Prostate, Bone, Spinal cord, Heart, Kidney, Breast, Appendix

Publications for Prostatic Hypertrophy

About this section

Articles related to Prostatic Hypertrophy:

(show top 50)    (show all 534)
idTitleAuthorsYear
1
Prostate Artery Embolization for Complete Urinary Outflow Obstruction Due to Benign Prostatic Hypertrophy. (27853823)
2017
2
Re: Stroke Associated with Alpha Blocker Therapy for Benign Prostatic Hypertrophy. (27321530)
2016
3
Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with I+-blockers. (27629686)
2016
4
Inhibitory Activities of Phenolic Compounds Isolated from Adina rubella Leaves Against 5I+-Reductase Associated with Benign Prostatic Hypertrophy. (27399661)
2016
5
Kidney transplant complications from undiagnosed benign prostatic hypertrophy. (25832848)
2015
6
Supplementary management of benign prostatic hypertrophy with Prostaquil. An 8-week registry. (26492588)
2015
7
The Impact of Medical and Surgical Treatment for Benign Prostatic Hypertrophy on Erectile Function. (26438220)
2015
8
Varicocele: the origin of benign prostatic hypertrophy? Testosterone dosages in the periprostatic plexus. (26290288)
2015
9
Clinical Outcomes of Transurethral Enucleation with Bipolar for Benign Prostatic Hypertrophy. (26662662)
2015
10
Effects of I+-blocker therapy on active duty military and military retirees for benign prostatic hypertrophy on diabetic complications. (25735029)
2015
11
The Role of Minimally Invasive Surgical Techniques in the Management of Large-gland Benign Prostatic Hypertrophy. (26543428)
2015
12
Re: Editorial comment on constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial: S. A. Kaplan J Urol 2013; 190: 1818-1819. (24892642)
2014
13
Estrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy. (25348255)
2014
14
Efficacy of Long-Term Daily Dosage of Alfuzosin 10 mg upon Sexual Function of Benign Prostatic Hypertrophy Patients: Two-Year Prospective Observational Study. (25606561)
2014
15
Bipolar transurethral resection versus monopolar transurethral resection for benign prostatic hypertrophy: a systematic review and meta-analysis. (24754254)
2014
16
Bilateral ureteral obstruction revealing a benign prostatic hypertrophy: a case report and review of the literature. (24513237)
2014
17
Preparation, characterization and stability study of dutasteride loaded nanoemulsion for treatment of benign prostatic hypertrophy. (25587300)
2014
18
Tadalafil and benign prostatic hypertrophy. Too risky. (24860894)
2014
19
Re: a phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. (25629105)
2014
20
Surgical therapy for benign prostatic hypertrophy/bladder outflow obstruction. (24744521)
2014
21
Re: Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial. (24120797)
2013
22
Correlation of transrectal and transabodominal ultrasound measurement of transition zone volume with post-operative enucleated adenoma volume in benign prostatic hypertrophy. (24876907)
2013
23
A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. (23642948)
2013
24
Alpha-1 adrenergic antagonists in aircrew for the treatment of benign prostatic hypertrophy. (23305000)
2013
25
Successful minimally-invasive management of a case of giant prostatic hypertrophy associated with recurrent nephrogenic adenoma of the prostate. (23565707)
2013
26
American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited. (22123290)
2012
27
Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial. (23089217)
2012
28
Sphaeranthus indicus attenuates testosterone induced prostatic hypertrophy in albino rats. (21503998)
2011
29
The early days of prostatectomy for benign prostatic hypertrophy. (22132481)
2011
30
Carvedilol for the treatment of benign prostatic hypertrophy in patients with heart failure? (21962427)
2011
31
Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. (21171937)
2011
32
Serenoa repens in benign prostatic hypertrophy: analysis of 2 Italian studies. (20944533)
2010
33
Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy. (21221201)
2010
34
Effect of Benincasa hispida fruits on testosterone-induced prostatic hypertrophy in albino rats. (24688153)
2010
35
Management of benign prostatic hypertrophy-related urinary retention: current trends and perspectives. (20027550)
2009
36
Pharmacological management of benign prostatic hypertrophy with phosphodiesterase-5 inhibitors. (20017412)
2009
37
Characteristic gene expression profiles of benign prostatic hypertrophy and prostate cancer. (19639170)
2009
38
Benign prostatic hypertrophy. (19737273)
2009
39
Transurethral resection of the prostate (TURP)--in the treatment of benign prostatic hypertrophy (BPH) in Mekelle, Ethiopia. (19743783)
2009
40
Acute colonic obstruction due to benign prostatic hypertrophy. (19405320)
2009
41
Oxidative stress in prostate hypertrophy and carcinogenesis]. (19644150)
2009
42
Increased frequency and nocturia in a middle aged male may not always be due to Benign Prostatic Hypertrophy (BPH): a case report. (19946479)
2009
43
Increased frequency and nocturia in a middle aged male may not always be due to benign prostatic hypertrophy: a case report. (20184712)
2009
44
Impact of alpha 1-adrenergic antagonist use for benign prostatic hypertrophy on outcomes in patients with heart failure. (19576359)
2009
45
Testosterone levels in benign prostatic hypertrophy and prostate cancer. (18362481)
2008
46
Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy. (18728700)
2008
47
Influence of dihydrotestosterone deficit on treatment of prostatic diseases regarding to contemporary methods of prostatic hypertrophy treatments]. (19205388)
2008
48
5-Alpha reductase inhibitors--benign prostatic hypertrophy and much more]. (18570285)
2008
49
Update on the use of dutasteride in the management of benign prostatic hypertrophy. (18044081)
2007
50
Finasteride: new indication. Benign prostatic hypertrophy: sexual disorders. (17724838)
2007

Variations for Prostatic Hypertrophy

About this section

Expression for genes affiliated with Prostatic Hypertrophy

About this section
Search GEO for disease gene expression data for Prostatic Hypertrophy.

Pathways for genes affiliated with Prostatic Hypertrophy

About this section

GO Terms for genes affiliated with Prostatic Hypertrophy

About this section

Biological processes related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1prostate gland growthGO:006073610.6AR, CYP19A1
2androgen metabolic processGO:000820910.5CYP19A1, ESR1
3positive regulation of phosphorylationGO:004232710.3AR, EGF
4positive regulation of MAPK cascadeGO:004341010.1ADRA1A, AR, CD36
5positive regulation of mitotic nuclear divisionGO:004584010.1EGF, FGF8
6positive regulation of cytosolic calcium ion concentrationGO:000720410.0ADRA1A, CD36, ESR1
7mammary gland alveolus developmentGO:006074910.0AR, EGF, ESR1
8negative regulation of gene expressionGO:001062910.0CD36, ESR1, PGR
9male gonad developmentGO:00085849.8AR, ESR1, SRY
10positive regulation of ERK1 and ERK2 cascadeGO:00703749.5ADRA1A, CD36, ESR1, FGF8
11transcription initiation from RNA polymerase II promoterGO:00063679.4AR, ESR1, PGR
12signal transductionGO:00071659.1ADRA1A, AR, EGF, ESR1, PGR

Molecular functions related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1ATPase bindingGO:00511179.8AR, ESR1, PGR
2steroid bindingGO:00054969.4AR, ESR1, PGR

Sources for Prostatic Hypertrophy

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet